Eli Lilly Reports Strong Q1 Earnings and Raises Guidance
Eli Lilly's stock surged 8.7% following its Q1 earnings report, which exceeded analyst expectations with $8.55 per share in non-GAAP earnings and $19.8 billion in sales. The company also raised its guidance, driven by strong performance in its GLP-1 drugs and growth in other divisions like immunology and oncology.
Tickers: $LLY
Topics: Company Guidance Earnings GLP-1 Drugs Revenue Growth Stock Price Movement